NeuroPace (NPCE) Stock Forecast, Price Target & Predictions
NPCE Stock Forecast
NeuroPace stock forecast is as follows: an average price target of $15.00 (represents a 30.10% upside from NPCE’s last price of $11.53) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
NPCE Price Target
The average price target for NeuroPace (NPCE) is $15.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 30.10% upside from NPCE's last price of $11.53.
NPCE Analyst Ratings
According to 5 Wall Street analysts, NeuroPace's rating consensus is 'Buy'. The analyst rating breakdown for NPCE stock is 0 'Strong Buy' (0.00%), 2 'Buy' (40.00%), 2 'Hold' (40.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).
NeuroPace Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 14, 2024 | Vik Chopra | Wells Fargo | $15.00 | $7.28 | 106.04% | 30.10% |
| May 23, 2024 | Frank Takkinen | Lake Street | $20.00 | $7.99 | 150.31% | 73.46% |
| Mar 14, 2024 | Larry Biegelsen | Wells Fargo | $20.00 | $13.63 | 46.74% | 73.46% |
| Nov 10, 2023 | Ross Osborn | Cantor Fitzgerald | $11.00 | $7.85 | 40.13% | -4.60% |
| Jul 15, 2022 | Morgan Stanley | $5.50 | $5.74 | -4.18% | -52.30% | |
| May 13, 2022 | Morgan Stanley | $6.00 | $5.96 | 0.67% | -47.96% |
The latest NeuroPace stock forecast, released on Aug 14, 2024 by Vik Chopra from Wells Fargo, set a price target of $15.00, which represents a 106.04% increase from the stock price at the time of the forecast ($7.28), and a 30.10% increase from NPCE last price ($11.53).
NeuroPace Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $18.33 |
| Last Closing Price | $11.53 | $11.53 | $11.53 |
| Upside/Downside | -100.00% | -100.00% | 58.98% |
In the current month, the average price target of NeuroPace stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to NeuroPace's last price of $11.53. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| May 29, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Mar 14, 2024 | Wells Fargo | Buy | Overweight | Upgrade |
| Feb 22, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jan 30, 2024 | Lake Street | Underperform | Underperform | Hold |
| Jan 30, 2024 | Leerink Partners | Buy | Buy | Hold |
| Dec 27, 2023 | Wells Fargo | Buy | Buy | Hold |
| Feb 22, 2023 | Piper Sandler | Neutral | Initialise | |
| Feb 22, 2023 | Cowen & Co. | Neutral | Initialise | |
| Feb 22, 2023 | Lake Street | Buy | Initialise | |
| Jul 15, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
| May 13, 2022 | Morgan Stanley | Underweight | Underweight | Hold |
NeuroPace's last stock rating was published by Wells Fargo on Aug 14, 2024. The company gave NPCE a "Overweight" rating, the same as its previous rate.
NeuroPace Financial Forecast
NeuroPace Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $16.43M | $16.51M | $14.47M | $12.79M | $11.16M | $10.20M | $11.37M | $11.00M | $10.34M | $12.63M | $11.22M |
| Avg Forecast | $28.00M | $27.00M | $26.00M | $23.00M | $24.03M | $23.20M | $22.23M | $21.12M | $20.90M | $19.07M | $18.30M | $17.33M | $17.41M | $14.22M | $12.63M | $12.18M | $12.40M | $9.90M | $11.08M | $10.64M | $11.00M | $10.80M | $11.17M | $10.98M |
| High Forecast | $28.96M | $27.92M | $26.89M | $23.79M | $24.85M | $23.99M | $22.99M | $21.85M | $21.17M | $19.73M | $18.30M | $17.33M | $18.00M | $14.71M | $13.06M | $12.59M | $12.82M | $9.90M | $11.08M | $10.64M | $11.00M | $10.80M | $11.17M | $10.98M |
| Low Forecast | $26.86M | $25.90M | $24.94M | $22.06M | $23.05M | $22.25M | $21.32M | $20.26M | $20.63M | $18.29M | $18.30M | $17.33M | $16.70M | $13.64M | $12.11M | $11.68M | $11.89M | $9.90M | $11.08M | $10.64M | $11.00M | $10.80M | $11.17M | $10.98M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.31% | 1.19% | 1.03% | 1.13% | 0.92% | 1.07% | 1.00% | 0.96% | 1.13% | 1.02% |
NeuroPace's average Quarter revenue forecast for Dec 23 based on 3 analysts is $17.41M, with a low forecast of $16.70M, and a high forecast of $18.00M. NPCE's average Quarter revenue forecast represents a 5.98% increase compared to the company's last Quarter revenue of $16.43M (Sep 23).
NeuroPace EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.95M | $-7.85M | $-8.02M | $-9.21M | $-9.14M | $-10.09M | $-8.88M | $-8.94M | $-6.18M | $-6.55M | $-6.89M |
| Avg Forecast | $-14.71M | $-14.18M | $-13.66M | $-12.08M | $-12.62M | $-12.19M | $-11.67M | $-11.10M | $-10.98M | $-10.02M | $-9.61M | $-9.10M | $-9.14M | $-7.47M | $-6.63M | $-6.40M | $-6.51M | $-5.41M | $-6.06M | $-8.27M | $-6.01M | $-5.91M | $-7.06M | $-6.00M |
| High Forecast | $-14.11M | $-13.60M | $-13.10M | $-11.59M | $-12.11M | $-11.69M | $-11.20M | $-10.64M | $-10.83M | $-9.61M | $-9.61M | $-9.10M | $-8.77M | $-7.17M | $-6.36M | $-6.13M | $-6.25M | $-5.41M | $-6.06M | $-6.62M | $-6.01M | $-5.91M | $-5.65M | $-6.00M |
| Low Forecast | $-15.21M | $-14.67M | $-14.13M | $-12.50M | $-13.05M | $-12.60M | $-12.07M | $-11.48M | $-11.12M | $-10.36M | $-9.61M | $-9.10M | $-9.46M | $-7.73M | $-6.86M | $-6.61M | $-6.74M | $-5.41M | $-6.06M | $-9.93M | $-6.01M | $-5.91M | $-8.47M | $-6.00M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 1.18% | 1.25% | 1.41% | 1.69% | 1.67% | 1.07% | 1.49% | 1.05% | 0.93% | 1.15% |
undefined analysts predict NPCE's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than NeuroPace's previous annual EBITDA (undefined) of $NaN.
NeuroPace Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-7.26M | $-9.12M | $-14.40M | $-12.43M | $-13.37M | $-14.41M | $-13.16M | $-8.83M | $-8.08M | $-8.49M | $-8.81M |
| Avg Forecast | $-2.94M | $-3.24M | $-4.12M | $-5.89M | $-5.45M | $-5.82M | $-6.70M | $-7.43M | $-7.26M | $-7.91M | $-8.83M | $-9.46M | $-9.27M | $-11.90M | $-13.84M | $-13.47M | $-14.72M | $-15.22M | $-12.98M | $-10.68M | $-9.52M | $-8.77M | $-9.15M | $-6.83M |
| High Forecast | $-2.79M | $-3.07M | $-3.90M | $-5.58M | $-5.16M | $-5.51M | $-6.34M | $-7.04M | $-6.68M | $-7.49M | $-8.36M | $-8.96M | $-8.43M | $-11.26M | $-13.10M | $-12.76M | $-13.94M | $-15.22M | $-12.98M | $-8.54M | $-9.52M | $-8.77M | $-7.32M | $-6.83M |
| Low Forecast | $-3.08M | $-3.38M | $-4.31M | $-6.15M | $-5.69M | $-6.07M | $-7.00M | $-7.77M | $-7.84M | $-8.26M | $-9.23M | $-9.88M | $-10.12M | $-12.43M | $-14.45M | $-14.07M | $-15.38M | $-15.22M | $-12.98M | $-12.82M | $-9.52M | $-8.77M | $-10.98M | $-6.83M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.61% | 0.66% | 1.07% | 0.84% | 0.88% | 1.11% | 1.23% | 0.93% | 0.92% | 0.93% | 1.29% |
NeuroPace's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NPCE's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
NeuroPace SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $13.39M | $14.48M | $13.43M | $13.57M | $12.55M | $12.77M | $12.44M | - | $9.42M | $9.53M | $8.27M |
| Avg Forecast | $24.15M | $23.28M | $22.42M | $19.84M | $20.72M | $20.01M | $19.17M | $18.22M | $18.03M | $16.45M | $15.78M | $14.94M | $15.01M | $12.27M | $10.89M | $10.50M | $10.69M | $8.54M | $9.56M | $9.18M | $9.49M | $9.31M | $10.26M | $9.47M |
| High Forecast | $24.97M | $24.08M | $23.19M | $20.51M | $21.43M | $20.69M | $19.82M | $18.84M | $18.26M | $17.01M | $15.78M | $14.94M | $15.53M | $12.69M | $11.26M | $10.86M | $11.06M | $8.54M | $9.56M | $9.18M | $9.49M | $9.31M | $12.31M | $9.47M |
| Low Forecast | $23.16M | $22.33M | $21.51M | $19.03M | $19.87M | $19.19M | $18.39M | $17.47M | $17.79M | $15.78M | $15.78M | $14.94M | $14.40M | $11.77M | $10.44M | $10.07M | $10.26M | $8.54M | $9.56M | $9.18M | $9.49M | $9.31M | $8.21M | $9.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 1.33% | 1.28% | 1.27% | 1.47% | 1.34% | 1.36% | - | 1.01% | 0.93% | 0.87% |
NeuroPace's average Quarter SG&A projection for Dec 23 is $15.01M, based on 3 Wall Street analysts, with a range of $14.40M to $15.53M. The forecast indicates a 12.14% rise compared to NPCE last annual SG&A of $13.39M (Sep 23).
NeuroPace EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.28 | $-0.36 | $-0.57 | $-0.50 | $-0.54 | $-0.59 | $-0.54 | $-0.37 | $-0.34 | $-0.48 | $-0.40 |
| Avg Forecast | $-0.10 | $-0.11 | $-0.14 | $-0.20 | $-0.18 | $-0.20 | $-0.23 | $-0.25 | $-0.25 | $-0.27 | $-0.30 | $-0.32 | $-0.31 | $-0.40 | $-0.47 | $-0.46 | $-0.50 | $-0.53 | $-0.45 | $-0.44 | $-0.33 | $-0.30 | $-0.34 | $-0.24 |
| High Forecast | $-0.09 | $-0.10 | $-0.13 | $-0.19 | $-0.18 | $-0.19 | $-0.22 | $-0.24 | $-0.23 | $-0.25 | $-0.28 | $-0.30 | $-0.29 | $-0.38 | $-0.45 | $-0.43 | $-0.47 | $-0.53 | $-0.45 | $-0.44 | $-0.33 | $-0.30 | $-0.34 | $-0.24 |
| Low Forecast | $-0.10 | $-0.11 | $-0.15 | $-0.21 | $-0.19 | $-0.21 | $-0.24 | $-0.26 | $-0.27 | $-0.28 | $-0.31 | $-0.34 | $-0.34 | $-0.42 | $-0.49 | $-0.48 | $-0.52 | $-0.53 | $-0.45 | $-0.44 | $-0.33 | $-0.30 | $-0.34 | $-0.24 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.77% | 1.25% | 1.00% | 1.02% | 1.31% | 1.22% | 1.12% | 1.12% | 1.43% | 1.67% |
According to undefined Wall Street analysts, NeuroPace's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NPCE previous annual EPS of $NaN (undefined).
NeuroPace Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LUNG | Pulmonx | $6.13 | $13.00 | 112.07% | Buy |
| KIDS | OrthoPediatrics | $22.46 | $39.50 | 75.87% | Buy |
| NVRO | Nevro | $4.05 | $5.84 | 44.20% | Hold |
| CNMD | CONMED | $71.23 | $97.00 | 36.18% | Buy |
| OFIX | Orthofix Medical | $17.93 | $24.00 | 33.85% | |
| NPCE | NeuroPace | $11.52 | $15.00 | 30.21% | Buy |
| IRMD | IRadimed | $53.00 | $60.00 | 13.21% | Buy |
| ITGR | Integer | $136.68 | $153.50 | 12.31% | Buy |
| FNA | Paragon 28 | $10.36 | $11.50 | 11.00% | Buy |
| CVRX | CVRx | $13.16 | $14.25 | 8.28% | Buy |
| AORT | Artivion | $28.90 | $30.75 | 6.40% | Buy |
| SRDX | Surmodics | $39.96 | $39.50 | -1.15% | Buy |
| GKOS | Glaukos | $146.35 | $144.14 | -1.51% | Buy |